Grant: Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
University of Calgary
$25,000.00
The microbiome of premature infants in asthma risk
EF 2018-19
Résumé
Premature infants face an increased risk for life-long diseases and treatments. Among the most compromised systems of premature infants is the lung function. In Canada and globally, very premature infants (between 28-32 wks gestation) and extremely premature (less than 28 wks gestation) babies are up to three and four times more likely to develop recurrent wheeze than term infants, respectively.
The causes of asthma remain unknown, yet recent exciting findings from infant studies and experimental animal models implicate the large community of microbes (microbiome) in the human gut as one of the causes of this disease. However, despite their heightened risk of asthma, and the more pronounced microbiome alterations linked to prematurity, none of the clinical studies performed to date have included this vulnerable infant population.
The influence of the microbiome in health outcomes should be ideally studied combining longitudinal prospective cohort studies and experimental work in animal models. Our team is currently conducting an unique study involving 385 infants at born at different gestational periods (ranging from extreme prematurity to term). Using an extensive sampling scheme of maternal and infant samples and statistical approaches to infer causality, our team will elucidate microbiome-derived features that may implicated with subsequent asthma risk. This analysis will inform studies in relevant animal models of asthma, which will corroborate causality and elucidate cellular and molecular mechanisms involved. This translational, multidisciplinary project is at the critical interface between human clinical studies and experimental animal work, and it has tremendous potential to inform future clinical studies aimed at preventing and/or ameliorating microbiome alterations in the preterm population.
Programme
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
399004
Name
Arrieta Mendez Marie-Claire
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Biomedical
Prcname2
Team Grant : Canadian Microbiome Initiative 2: Research Teams
Projecttitle
The microbiome of premature infants in asthma risk
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Keyworddelim
Asthma; Early-Life Microbiome; Gut Microbiome; Prematurity; Systems Biology
Abstract
Premature infants face an increased risk for life-long diseases and treatments. Among the most compromised systems of premature infants is the lung function. In Canada and globally, very premature infants (between 28-32 wks gestation) and extremely premature (less than 28 wks gestation) babies are up to three and four times more likely to develop recurrent wheeze than term infants, respectively.
The causes of asthma remain unknown, yet recent exciting findings from infant studies and experimental animal models implicate the large community of microbes (microbiome) in the human gut as one of the causes of this disease. However, despite their heightened risk of asthma, and the more pronounced microbiome alterations linked to prematurity, none of the clinical studies performed to date have included this vulnerable infant population.
The influence of the microbiome in health outcomes should be ideally studied combining longitudinal prospective cohort studies and experimental work in animal models. Our team is currently conducting an unique study involving 385 infants at born at different gestational periods (ranging from extreme prematurity to term). Using an extensive sampling scheme of maternal and infant samples and statistical approaches to infer causality, our team will elucidate microbiome-derived features that may implicated with subsequent asthma risk. This analysis will inform studies in relevant animal models of asthma, which will corroborate causality and elucidate cellular and molecular mechanisms involved. This translational, multidisciplinary project is at the critical interface between human clinical studies and experimental animal work, and it has tremendous potential to inform future clinical studies aimed at preventing and/or ameliorating microbiome alterations in the preterm population.
Competitiondate
201811
Approvedterm2
1 yr 0 mth
Pinamesdelim
Arrieta Mendez, Marie-Claire; Azad, Meghan; Giesbrecht, Gerald F; Kembel, Steven W; Kozyrskyj, Anita L; Lacaze-Masmonteil, Thierry; Langille, Morgan G; McNagny, Kelly M
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $25,000~ $0~